Bloomage Biotechnology Corp, a mainland firm involved in the production of hyaluronic acid products, is seeking to raise about HK$100 million through a listing on the Hong Kong main board next month. Proceeds would be used to fund capacity expansion to meet demand, sources said. Local investment bank Hantec Capital is sponsoring the offering. The firm received the green light from the Hong Kong stock exchange late last month and depending on market sentiment would like to kick off the international offering in the next two weeks, one source said. The Shandong-based firm that specialises in the production of hyaluronic acid used for medical, cosmetic and food products had total sales of about 100 million yuan (HK$114 million) last year. About 60 per cent of its products are sold in the domestic market with the rest going overseas. 'Bloomage is only focused on a business-to-business model and is not keen on selling goods to end customers,' said one source.